PARIS: European shares closed higher on Monday as a soft business activity reading strengthened the case for more monetary ...

Shares of Skye Bioscience gained after the San Diego biopharmaceutical company highlighted the safety of its in-development obesity treatment as compared with rivals. AstraZeneca shares slipped after ...

The experimental precision drug, developed with Japan's Daiichi Sankyo, did not significantly improve overall survival rates ...

AstraZeneca stock slumped Monday after its Daiichi Sankyo-partnered drug missed its mark in a study of patients with breast ...

UniCredit shares closed 3.3% lower. AstraZeneca lost 1.7% after its experimental precision drug developed with Daiichi Sankyo ...

Despite showing a progression-free survival benefit, the antibody-drug conjugate did not improve overall survival in HR-positive, HER2-negative or -low breast cancer.

A cancer drug being developed by AstraZeneca failed to "achieve statistical significance" in helping patients live longer ...

A dark money anti-pharma bus —A rare disease treatment approval for Zevra —An FTC lawsuit against pharmacy benefit managers ...

It is a fictional representation created for illustrative purposes only. AstraZeneca's experimental precision drug, developed ...

Japanese AI startup Rutilea has completed work on a new data center in Fukushima. "We announce that AI Fukushima Inc. has ...

It said the drug did not 'achieve statistical significance' in terms of the survival rates of those suffering from breast ...